The Attune® Knee System, made by Johnson & Johnson subsidiary DePuy Synthes, is a popular knee replacement device. It was promoted to patients with the promise of better range of motion and stability. Despite these claims, the Food and Drug Administration (FDA) has received numerous reports of device failure from patients, particularly loosening of tibial parts – which may lead to revision surgery/surgeries.
Painful Side Effects and Revision Surgeries
When patients suffer complications, additional surgery is often necessary to remove the implant or components of the implant. Revision surgery is invasive, painful, and may require months of recovery. Sadly, in some cases, device failure can happen only months after the initial procedure. Examples of device failure include:
- Dissociation of the Implant
Symptoms of device failure include:
- Joint Instability
- Warmth of the Joint
- Redness of the Skin
Other Defective DePuy Devices
DePuy has dealt with thousands of lawsuits in recent years over its joint implants. In August 2010, DePuy recalled more than 90,000 Hip Systems after receiving data regarding a higher than expected rate of failure and revision surgery associated with these hip implants.
More recently, in December 2016, DePuy recalled its elbow implant, the Synthes Radial Head Prosthesis System because of the possibility that the radial stem may loosen post-operatively at the stem bone interface.
Take Legal Action
If you or a loved one suffered complications after a knee replacement and had corrective surgery or, if your doctor recommended you have additional surgery, you may be entitled to compensation.
Contact Sokolove Law now for a free, confidential legal consultation. Even if you’re unsure which brand of implant was used in your surgery, we may still be able to determine if you can take legal action. Our knowledgeable case managers are available 24/7 to assist you.
Note – Any medical decision is important. Please consult your physician before making any medical decision. All brands are trademarks of their respective companies.